Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

Laurent Phely; Luca Hensen; Christoph Faul; Christer Alexander Ruff; Dina Schneider; Wolfgang Andreas Bethge; Claudia Lengerke

doi:10.1001/jamaoncol.2024.0473

Allogeneic CD19/CD22 CAR T-Cell Therapy for B-Cell Acute Lymphoblastic Leukemia

JAMA Oncol. 2024 Apr 18. doi: 10.1001/jamaoncol.2024.0473. Online ahead of print.

Authors

Laurent Phely¹, Luca Hensen¹, Christoph Faul¹, Christer Alexander Ruff², Dina Schneider³, Wolfgang Andreas Bethge¹, Claudia Lengerke¹

Affiliations

¹ Department of Internal Medicine II, Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tuebingen, Germany.
² Department of Diagnostic and Interventional Neuroradiology, University Hospital Tubingen, Tubingen, Germany.
³ Miltenyi Biotec, Gaithersburg, Maryland.

PMID: 38635232
DOI: 10.1001/jamaoncol.2024.0473

No abstract available

Plain language summary

This case series reports durable remissions in 2 patients with relapsed/refractory B-cell acute lymphoblastic leukemia treated with allogeneic bispecific CD19/CD22-targeting chimeric antigen receptor T cells.